These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16400461)

  • 1. Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation.
    Spinelli GA; Felipe CR; Machado PG; Garcia R; Casarini DE; Moreira SR; Park SI; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2006 Jan; 39(1):19-30. PubMed ID: 16400461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.
    Machado PG; Felipe CR; Park SI; Garcia R; Moreira S; Casarini D; Franco M; Alfieri F; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2004 Sep; 37(9):1303-12. PubMed ID: 15334195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
    Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
    Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function.
    Perrea DN; Moulakakis KG; Poulakou MV; Vlachos IS; Nikiteas N; Kostakis A
    Int Urol Nephrol; 2008; 40(2):521-7. PubMed ID: 17978855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
    Chueh SC; Kahan BD
    Transplantation; 2003 Jul; 76(2):375-82. PubMed ID: 12883196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
    Spinelli GA; Felipe CR; Park SI; Mandia-Sampaio EL; Tedesco-Silva H; Medina-Pestana JO
    Transplant Proc; 2011 Dec; 43(10):3730-7. PubMed ID: 22172836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.
    Claes K; Meier-Kriesche HU; Schold JD; Vanrenterghem Y; Halloran PF; Ekberg H
    Nephrol Dial Transplant; 2012 Feb; 27(2):850-7. PubMed ID: 21617197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF; Wachs ME; Trouillot TE; Bak T; Kugelmas M; Kam I; Everson G
    Liver Transpl; 2001 May; 7(5):401-8. PubMed ID: 11349259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia.
    Hricik DE; Mayes JT; Schulak JA
    Am J Kidney Dis; 1991 Sep; 18(3):353-8. PubMed ID: 1882828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.
    Bai S; Brunner LJ; Stepkowski SM; Napoli KL; Kahan BD
    Transplantation; 2001 Jun; 71(11):1585-92. PubMed ID: 11435969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.